ArticleInorganic chemistry2026
Speciation, Protein Binding, Biotransformation, and Cytotoxicity of a VV-Lactate Complex.
Article in Inorganic chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
We studied the speciation, protein binding, biotransformation, and cytotoxicity of the dioxidovanadium(V) lactate complex Cs2[VV2O4(lact)2]·2H2O and compared the results with those obtained for the analogous malate compound. 51V NMR and ESI-MS results show that Cs2[VV2O4(lact)2]·2H2O forms [VVO2]+, [H2VVO4]-, [H2VV2O7]2-, [VV2O4(lact)2]2-, [VV3O7(lact)2]3-, [VV4O12]4-, [VV5O15]5-, [VVO2(lact)(H2O)]-, [VVO2(lact)(OH)]2-, and [VV10O28]6- species in aqueous solution. In the presence of lysozyme, the amounts of [VV10O28]6- and [VVO2(lact)(H2O)]- significantly decrease and protein adducts with [VV2O4(lact)2]2- and [VVO(lact)2]- are detected by ESI-MS. X-ray structures of the adducts show noncovalent binding of [VIVO]2+, [VVO2]+, [VV2O4(lact)2]2-, cyclic [VV3O9]3-, and [VV3O7(lact)2]3- to lysozyme. Cs2[VV2O4(lact)2]·2H2O and Cs2[VV2O4(mal)2]·2H2O exhibit higher cytotoxicity than cisplatin on PC-3 cancer cells (IC50 values are 5.9 ± 0.3 and 5.0 ± 0.3 μM, respectively), while they are less active than cisplatin against HeLa cells and less selective against BALB/c-3T3 and HaCaT cells. In systems containing [VV2O4(lact)2]2- and biological reductants, EPR studies demonstrate the formation of hydroxyl radicals, supporting a mechanism in which redox cycling between VV and VIV contributes to the oxidative stress that accounts for the observed biological activity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.